106 related articles for article (PubMed ID: 3613958)
1. Hepatobiliary MR contrast agents: 5-substituted iron-EHPG derivatives.
Lauffer RB; Vincent AC; Padmanabhan S; Villringer A; Saini S; Elmaleh DR; Brady TJ
Magn Reson Med; 1987 Jun; 4(6):582-90. PubMed ID: 3613958
[TBL] [Abstract][Full Text] [Related]
2. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
J Comput Assist Tomogr; 1985; 9(3):431-8. PubMed ID: 3989032
[TBL] [Abstract][Full Text] [Related]
3. Fe(III)-EHPG and Fe(III)-5-Br-EHPG as contrast agents in MRI: an animal study.
Liu GC; Wang YM; Jaw TS; Chen HM; Sheu RS
J Formos Med Assoc; 1993 Apr; 92(4):359-66. PubMed ID: 8104585
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of Fe-(5-C2H5-EHPG)- as a contrast agent in MR imaging of hepatobiliary system.
Sheu RS; Liu GC; Wang YM; Jaw TS; Chen HM; Kuo YT
Kaohsiung J Med Sci; 1997 Feb; 13(2):75-85. PubMed ID: 9099045
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents.
Hoener B; Engelstad BL; Ramos EC; Macapinlac HA; Price DC; Johnson TR; White DL
J Magn Reson Imaging; 1991; 1(3):357-62. PubMed ID: 1802149
[TBL] [Abstract][Full Text] [Related]
6. Iron-EHPG as an hepatobiliary MR contrast agent: initial imaging and biodistribution studies.
Lauffer RB; Greif WL; Stark DD; Vincent AC; Saini S; Wedeen VJ; Brady TJ
Int J Rad Appl Instrum B; 1988; 15(1):47-9. PubMed ID: 3350696
[No Abstract] [Full Text] [Related]
7. Albumin binding of paramagnetic hepatobiliary contrast agents: enhancement of outer sphere relaxivity.
Lauffer RB; Betteridge DR; Padmanabhan S; Brady TJ
Int J Rad Appl Instrum B; 1988; 15(1):45-6. PubMed ID: 3350695
[No Abstract] [Full Text] [Related]
8. Investigation of physicochemical and in-vivo behavior of diastereomeric iron-59, gallium-68, and indium-111-EHPG trivalent metal complexes.
Madsen SL; Bannochie CJ; Martell AE; Mathias CJ; Welch MJ
J Nucl Med; 1990 Oct; 31(10):1662-8. PubMed ID: 2213190
[TBL] [Abstract][Full Text] [Related]
9. Pulse sequence optimization for MR imaging using a paramagnetic hepatobiliary contrast agent.
Greif WL; Buxton RB; Lauffer RB; Saini S; Stark DD; Wedeen VJ; Rosen BR; Brady TJ
Radiology; 1985 Nov; 157(2):461-6. PubMed ID: 4048456
[TBL] [Abstract][Full Text] [Related]
10. EHPG iron(III) complexes as potential contrast contrast agents for MRI.
Kuźnik N; Jewuła P; Oczek L; Kozłowicz S; Grucela A; Domagała W
Acta Chim Slov; 2014; 61(1):87-93. PubMed ID: 24664331
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
12. MR imaging of blood-borne liver metastases in mice: contrast enhancement with Fe-EHPG.
Shtern F; Garrido L; Compton C; Swiniarski JK; Lauffer RB; Brady TJ
Radiology; 1991 Jan; 178(1):83-9. PubMed ID: 1984329
[TBL] [Abstract][Full Text] [Related]
13. TMPHPG: a lipophilic derivative of EHPG for iron, gallium-68 and indium-111 hepatobiliary clearance.
Madsen SL; Bannochie CJ; Welch MJ; Mathias CJ; Martell AE
Int J Rad Appl Instrum B; 1991; 18(3):289-94. PubMed ID: 2071441
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical properties, biodistribution, and imaging characteristics of manganese-mesoporphyrin. A potential hepatobiliary contrast agent for magnetic resonance imaging.
Schmiedl UP; Nelson JA; Robinson DH; Michalson A; Starr F; Frenzel T; Ebert W; Schuhmann-Giampieri G
Invest Radiol; 1993 Oct; 28(10):925-32. PubMed ID: 8262747
[TBL] [Abstract][Full Text] [Related]
15. Site-specific water proton relaxation enhancement of iron(III) chelates noncovalently bound to human serum albumin.
Jenkins BG; Armstrong E; Lauffer RB
Magn Reson Med; 1991 Jan; 17(1):164-78. PubMed ID: 1648652
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system.
Schuhmann-Giampieri G; Schmitt-Willich H; Press WR; Negishi C; Weinmann HJ; Speck U
Radiology; 1992 Apr; 183(1):59-64. PubMed ID: 1549695
[TBL] [Abstract][Full Text] [Related]
17. Phantom and animal studies of a new hepatobiliary agent for MR imaging: comparison of Gd-DTPA-DeA with Gd-EOB-DTPA.
Yoshikawa K; Inoue Y; Akahane M; Shimada M; Itoh S; Seno A; Hayashi S
J Magn Reson Imaging; 2003 Aug; 18(2):204-9. PubMed ID: 12884333
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-phthalein complexone as a contrast agent for hepatobiliary MR imaging.
Kawamura Y; Endo K; Koizumi M; Watanabe Y; Saga T; Konishi J; Horiuchi K; Yokoyama A
J Comput Assist Tomogr; 1989; 13(1):67-70. PubMed ID: 2910950
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and imaging performance of a new class of macrocyclic hepatobiliary MR contrast agents.
Marinelli ER; Neubeck R; Song B; Wagler T; Ranganathan RS; Sukumaran K; Wedeking PW; Nunn A; Runge VM; Tweedle MF
Invest Radiol; 2000 Jan; 35(1):8-24. PubMed ID: 10639032
[TBL] [Abstract][Full Text] [Related]
20. UV and fluorescence spectral changes induced by neodymium binding of N,N'-ethylenebis[2-(o-hydroxyphenolic)glycine] and N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N' diacetic acid.
Wang Z; Yang B
Spectrochim Acta A Mol Biomol Spectrosc; 2006 Nov; 65(3-4):946-9. PubMed ID: 16684618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
